FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Whelan

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Physiology

Disease Progression

Procedures

Co-author Network

Publications

TOP 3
Urs E Studer; Laurence Collette; Peter Whelan; Walter Albrecht; Jacques Casselman; Theo M de Reijke; Hartmut Knönagel; Wolfgang Loidl; Santiago Isorna; Subramanian K Sundaram; Muriel Debois
Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
Urs E Studer; Peter Whelan; Walter Albrecht; Jacques Casselman; Theo M de Reijke; Dieter Hauri; Wolfgang Loidl; Santiago Isorna; Subramanian K Sundaram; Muriel Debois; Laurence Collette
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.
Fritz H Schröder; Peter Whelan; Theo M de Reijke; Karl-Heinz Kurth; Michele Pavone-Macaluso; Johan Mattelaer; Roland F Van Velthoven; Muriel Debois; Laurence Collette
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Whelan (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Urs E Studer; Laurence Collette; Peter Whelan; Walter Albrecht; Jacques Casselman; Theo M de Reijke; Hartmut Knönagel; Wolfgang Loidl; Santiago Isorna; Subramanian K Sundaram; Muriel Debois
Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
European urology 2008;53(5):941-9.
2006: Urs E Studer; Peter Whelan; Walter Albrecht; Jacques Casselman; Theo M de Reijke; Dieter Hauri; Wolfgang Loidl; Santiago Isorna; Subramanian K Sundaram; Muriel Debois; Laurence Collette
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(12):1868-76.
2004: Fritz H Schröder; Peter Whelan; Theo M de Reijke; Karl-Heinz Kurth; Michele Pavone-Macaluso; Johan Mattelaer; Roland F Van Velthoven; Muriel Debois; Laurence Collette
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
European urology 2004;45(4):457-64.
2003: Walter Albrecht; Laurence Collette; Cesare Fava; Oleg B Kariakine; Peter Whelan; Urs E Studer; Theo M de Reijke; Paul J Kil; Lesley A Rea
Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study.
European urology 2003;44(5):505-11.
2003: Paul J Kil; H M J Goldschmidt; B J A Wieggers; O B Kariakine; Urs E Studer; Peter Whelan; JW Hetherington; Theo M de Reijke; J W Hoekstra; Laurence Collette
Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma.
European urology 2003;43(1):31-8.
1998: Alan Horwich; Robert A Huddart; J Gadd; P J Boyd; JW Hetherington; Peter Whelan; David P Dearnaley
A pilot study of intermittent androgen deprivation in advanced prostate cancer.
British journal of urology 1998;81(1):96-9.